- +1 858 909 0079
- +1 858 909 0057
- [email protected]
- +1 858 909 0079
- [email protected]
Cat# | Product Name | Swiss Prot# | Size | Price (US$) | Order |
PN1220 | Recombinant Protein-Murine coronavirus Spike protein S1 (a.a.15 to 415) | P11224 | 100 µg | 1195 | |
PN1221 | Recombinant Protein-Murine coronavirus Spike protein S2 (a.a.718 to 1118) | P11224 | 100 µg | 1195 | |
PN1222 | Recombinant Protein-Murine coronavirus inf-MHV-A59 Nucleocapsid protein (a.a.51 to 454) | C0KYY3 | 100 µg | 1195 | |
RPN1220 | cDNA-Murine coronavirus Spike protein S1 (a.a.15 to 415) | P11224 | 2 µg | 2000 | |
RPN1221 | cDNA-Murine coronavirus Spike protein S2 (a.a.718 to 1118) | P11224 | 2 µg | 2000 | |
RPN1222 | cDNA-Murine coronavirus inf-MHV-A59 Nucleocapsid protein (a.a.51 to 454) | C0KYY3 | 2 µg | 2015 |
Murine coronavirus cDNA and recombinant antigen
Murine coronavirus is a type of coronavirus that infects mice and is a valuable model system for studying the pathogenesis of human coronaviruses. The virus is composed of several proteins, including the spike proteins S1 and S2, which are important for virus entry into host cells, and the nucleocapsid protein, which is involved in viral replication and packaging.
The spike protein S1 and S2 are the major components of the viral envelope and are responsible for viral entry into host cells by binding to the host cell receptor. The nucleocapsid protein is a structural protein that packages the viral RNA genome and plays an important role in viral replication.
Studies of murine coronavirus have contributed significantly to our understanding of coronavirus biology and pathogenesis and have helped to inform the development of therapeutics and vaccines for human coronavirus infections.
The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E.coli expression Vector), which are ready for production of the recombinant proteins.
Get the Latest News and Updates by Email
6393 Nancy Ridge Dr. Suite A
San Diego, CA 92121 USA
Fax: +1-858-909-0057
Get the Latest News and Updates by Email
© 2023 Bioclone Inc. All Rights Reserved.
Magnetic Beads Make Things Simple